Phase III ATTAIN trial data of Vibativ in hospital-acquired pneumonia published in Infectious Diseases and Therapy.- Cumberland Pharma

Cumberland Pharmaceuticals has announced a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of Vibativ (telavancin) compared to vancomycin within a subset of patients who were enrolled in phase III ATTAIN trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. Cumberland manufactures and distributes telavancin under the brand name Vibativ. The overall clinical cure rate for telavancin was 85.4% versus 74.3% for vancomycin with a 95% confidence interval 11.1% (- 0.002%, 22.2).

In addition, several other sub-group analyses also demonstrated where telavancin was numerical superiority over vancomycin, including patients age at least 65, patients with APACHE II at least 20, and patients with VAP. Renal function changes and or other AEs were comparable between treatment groups. In settings where organisms with vancomycin MIC at least 1.0 microg/mL are prevalent, telavancin is an alternative to vancomycin for empiric or specific coverage of MRSA in patients with HAP/VAP.

See: "Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials" Michael S. Niederman et al. Infectious Diseases and Therapy (2019) 8: 445. https://doi.org/10.1007/s40121-019-0255-0